Progressive Trends in Development of 505 b (2) Formulations Over Generic Formulations

Abstract

The pharmaceutical landscape is constantly evolving, with drug developers seeking innovative pathways to bring new and improved therapies to patients. While generic formulations have traditionally played a crucial role in ensuring affordable access to medicines, the 505(b)(2) regulatory pathway has emerged as a strategic avenue for developing differentiated products that offer advantages over their generic counterparts. This review article explores the progressive trends in leveraging the 505(b)(2) pathway to create novel formulations that address unmet clinical needs, enhance patient compliance, improve drug efficacy and safety, and ultimately provide added value beyond that offered by conventional generic equivalents. We will delve into the key drivers behind this trend, the various formulation strategies employed, and the implications for both pharmaceutical companies and patients.

Keywords

505(b)(2) pathway, generic formulations, drug development, formulation strategies, intellectual property, market exclusivity, patient compliance, drug delivery systems, modified release, combination products.

Introduction

5.4 Switches  from prescription product to OTC product -

The transition from prescription (Rx) to over-the-counter (OTC) products using the 505(b)(2) regulatory pathway is a growing trend in drug development. This transition is often driven by a combination of regulatory flexibility, commercial strategy, and patient-centric innovation.

Examples -

1) Zyrtec OTC (Cetirizine)

Original Rx Indication: Allergic rhinitis and chronic urticaria.

OTC Indication: Relief of allergy symptoms.

505(b)(2) Innovation: Utilized pediatric and adult safety data to support OTC use.

Approval Year: 2008

Reference: FDA Zyrtec Info

2) Prilosec OTC (Omeprazole)

Original Rx Indication: Treatment of GERD, ulcers, and other acid-related disorders.

OTC Indication: Relief of frequent heartburn.

505(b)(2) Innovation: Re-labeled for self-limited OTC use with a 14-day regimen.

Approval Year: 2003

Reference: FDA Announcement

5.5  Advanced Drug Delivery Systems:

1. Nanoparticle-Based Formulations:

Utilizing nanotechnology to enhance drug solubility, bioavailability, and targeted delivery to specific tissues or cells, potentially improving efficacy and reducing systemic side effects (Ferrari, 2005).

2. Liposomal Formulations:

Encapsulating drugs within liposomes (vesicles composed of lipid bilayers) can improve drug stability, prolong circulation time, and enhance drug delivery to target sites (Gregoriadis, 2016).

3. Microsphere Formulations:

 Incorporating drugs into small polymeric spheres for controlled release over extended periods, often administered via injection (Freiberg & Zhu, 2004).

4. Prodrug Formulations:

Developing pharmacologically inactive derivatives of an active drug that undergo enzymatic or chemical conversion in the body to release the active drug. This strategy can improve drug solubility, permeability, stability, or reduce side effects (Rautio et al., 2008)

5. Isomeric Switches and Salt Modifications:

While sometimes pursued through ANDAs, the 505(b)(2) pathway can be utilized when additional clinical data is required to support the improved efficacy or safety profile of a single isomer or a novel salt form compared to the RLD (Bolla et al., 2010).

1) Isomeric switches -

Product Name - Escitalopram (Lexapro®)

Parent drug: Citalopram (Celexa®) – racemic mix of R- and S-isomers.

Switch: S-isomer (Escitalopram) has primary serotonin reuptake inhibitory activity.

Innovation: Immediate-release tablets with higher therapeutic index.

Clinical Benefit:

• Greater efficacy at lower doses.
• Faster onset of action and fewer cognitive side effects.

Regulatory Note: Approved under 505(b)(2) leveraging Celexa safety/efficacy data.

Reference: FDA label for Lexapro [NDA 021323].

2) Salt modification -

Product Name - Quazepam Dihydrochloride (Doral®)

Parent drug: Quazepam (free base).

Salt Modification: Used dihydrochloride salt to enhance solubility and shelf stability.

Rationale: The salt form provides a slower onset and longer half-life, ideal for sleep maintenance.

Clinical Benefit:

• Effective for insomnia with less rebound.
• Once-daily dosing with reduced morning sedation.

Regulatory Note: Approved under 505(b)(2) as a salt of a known drug.

6.  Case Studies Illustrating Progressive Trends:

Several successful 505(b)(2) products exemplify the progressive trends discussed above:

6.1 Case study 1 – Suboxone® sublingual film (Buprenorphine/Naloxone)

Background

Innovator product - Suboxone® sublingual tablet (Buprenorphine/Naloxone)

Problem with innovator product – High risk of misuse and medication diversion (e.g., tablets being crushed and injected)

505 (b)(2) development - 

• Innovation – Development of sublingual film version that dissolve quickly under the tounge,is individually packaged, and offer better dosing precision.
• Regulatory path – Applied through the 505 (b)(2) pathway by referencing the original tablet data, with limited bridging studies to demonstrate bioequivalence between the tablet and film.
• Bridging studies – only comparative pharmacokinetics study required no needs of full clinical trials.
• Advantages - 

• Faster onset of action compared to the tablet.
• Increased patient compliance due to easier administration.
• Reduce risk of diversion and misuse.

• Market impact - Suboxone® film gained 3 years of market exclusivity and quickly dominated the opioid dependence treatment market, outpacing the original tablet.

Reference - Suboxone Sublingual Film (NDA 022410)

6.2 Case study 2 – DepoSubQ-Provera 104® (Medroxyprogesterone Acetate Subcutaneous Injection)

Background

Innovator product - Depo-Provera® intramuscular (IM) injection (150 mg) was used for contraception.

Problem with innovator product - IM injections were painful, needed trained professionals for administration, and patients disliked frequent clinic visits.

505(b)(2) development - 

• Innovation – Modified the route from IM (intramuscular) to SC (subcutaneous).Reduced dose from 150 mg (IM) to 104 mg (SC) while maintaining contraceptive efficacy.Relied on prior clinical experience/data with Depo-Provera®.
• Regulatory path – Filed a 505(b)(2) NDA to rely on existing Depo-Provera® safety/efficacy data.Supplemented with bridging PK and clinical studies.
• Bridging studies – Pharmacokinetic (PK) studies comparing blood levels of the drug between IM and SC forms. Smaller clinical trials to demonstrate that 104 mg SC produced comparable contraceptive protection.
• Advantages - 

• Less painful and easier administration.
• Potential for self-administration by patients.
• Lower dose reduced systemic exposure.

• Market impact - Approved in 2004. Created a new market niche for subcutaneous contraceptive injections. Gained 3 years of market exclusivity.

Reference - Depo-SubQ Provera 104 (NDA 021583)

6.3 Case study 3 – Treximet® (Sumatriptan + Naproxen Sodium Combination Tablet)

Background

Innovator product - Sumatriptan (Imitrex®) was effective for migraine, but some patients needed anti-inflammatory help. Naproxen sodium (Aleve®) was commonly used separately for inflammation.

505 (b)(2) development - 

• Innovation – Developed a fixed-dose combination (FDC) tablet of sumatriptan 85 mg + naproxen sodium 500 mg. Treat migraine pain and underlying inflammation together in a single dose.Referenced existing individual drug data under 505(b)(2).
• Regulatory path – Filed through 505(b)(2) NDA referencing the original drugs’ data. Bridging clinical studies to prove combination superiority.
• Bridging studies – Conducted Phase III clinical trials comparing Treximet® vs. each drug alone. Proved superior efficacy of combination therapy over monotherapy in reducing migraine symptoms.
• Advantages - 

• One pill targeting multiple migraine mechanisms.
• Simplified treatment.
• Increased patient compliance and satisfaction.

• Market impact - Approved by FDA in 2008. Rapidly adopted by neurologists and general physicians. Gained 3 years of market exclusivity under 505(b)(2) rules.

Reference - Treximet (NDA 021926)

6.4 Case study 4 – Cabenuva® (Cabotegravir + Rilpivirine Long-Acting Injectable)

Background

Innovator product - Cabotegravir and rilpivirine were originally developed as oral tablets for treating HIV-1.

Problem with innovator product - Daily oral pills posed challenges like adherence issues and pill fatigue in HIV patients.

505(b)(2) development - 

• Innovation – Formulated a long-acting intramuscular (IM) injectable version (Cabenuva®), administered once a month. Relied on existing safety and efficacy data from oral cabotegravir/rilpivirine. Bridging pharmacokinetic and clinical efficacy studies conducted.
• Regulatory path - Submitted under 505(b)(2) NDA, referencing oral formulations (Tivicay®, Edurant®). Supplemented with new injection-specific studies.
• Bridging studies – FLAIR and ATLAS Phase III trials compared injectable vs oral therapies. Showed that monthly IM injections were non-inferior to daily oral tablets.
• Advantages - 

• Reduced pill burden (1 injection/month instead of 30+ pills).
• Improved patient compliance and satisfaction.
• Expanded treatment options for HIV maintenance therapy.

• Market impact - FDA approved Cabenuva® in January 2021. First complete long-acting injectable HIV treatment approved.

Reference - Cabenuva (NDA 212888).

6.5 Case study 5  – Mounjaro® (Tirzepatide Injection)

Background

Innovator product - Tirzepatide was initially explored in oral small molecule formulations targeting GLP-1/GIP receptors

Problem with innovator product – Oral versions had limited bioavailability and poor control over dose delivery.

505 (b)(2) development - 

• Innovation – Shifted development focus to once-weekly subcutaneous injection form. Designed as a dual GIP and GLP-1 receptor agonist.Relied on prior scientific knowledge of incretin therapies (e.g., semaglutide, liraglutide).
• Regulatory path – 505(b)(2) NDA pathway leveraging existing GLP-1 data plus new clinical studies.
• Bridging studies – Phase III SURPASS program: SURPASS-1 to SURPASS-5 studies evaluated tirzepatide SC vs. placebo and comparators (semaglutide, insulin). Established superiority over comparators in blood sugar reduction and weight loss.
• Advantages - 

• Potent glucose control plus significant weight loss.
• Weekly injection increased compliance vs. daily pills.

• Market impact - FDA approved Mounjaro® in May 2022 for type 2 diabetes. Expanded indications into obesity treatment under investigation.

Reference - Mounjaro (NDA 215866).

6.6 Case study 6  – Kynmobi® (Apomorphine Sublingual Film)

 Background

Innovator product - Apomorphine was used in injectable form for Parkinson's disease OFF episodes.

Problem with innovator product – Injection during tremors is difficult.

505(b)(2) development - 

• Innovation – Developed sublingual film of apomorphine. Thin film placed under the tongue — rapidly dissolves and delivers drug. Avoids painful injections.
• Regulatory path – Approved under 505(b)(2) NDA pathway.
• Bridging studies – Referenced prior SC apomorphine data (Apokyn®). New studies demonstrated PK/PD comparability.
• Advantages - 

• Needle-free rescue therapy for Parkinson’s OFF episodes.
• Easy administration during tremor crises.

• Market impact - FDA approval in May 2020.

Reference - Kynmobi (NDA 210875).

7. Challenges and Considerations in 505(b)(2) Formulation Development:

While the 505(b)(2) pathway offers significant advantages, it also presents certain challenges:

• Reliance on the RLD: The success of a 505(b)(2) application is inherently linked to the safety and efficacy data of the RLD. Any issues or changes related to the RLD can impact the 505(b)(2) product.
• Demonstrating Clinical Benefit: Depending on the nature of the formulation change, the FDA may require clinical studies to demonstrate a meaningful improvement in safety or efficacy compared to the RLD (Food and Drug Administration, 1999).
• Intellectual Property Landscape: Navigating the patent landscape surrounding the RLD and developing novel formulations that do not infringe on existing patents can be complex (Thomas, 2011).
• Regulatory Uncertainty: The specific requirements and expectations of the FDA for 505(b)(2) applications can sometimes be less clearly defined compared to ANDAs or traditional NDAs (Gansler et al., 2012).
• Manufacturing Complexity: Developing and scaling up the manufacturing of novel formulations, particularly advanced drug delivery systems, can present significant technical challenges.

8. Conclusion and Future Perspectives:

The development of differentiated 505(b)(2) formulations represents a significant and progressive trend in the pharmaceutical industry. By strategically leveraging this regulatory pathway, companies can create products that offer tangible benefits over generic formulations, addressing unmet clinical needs, enhancing patient compliance, and potentially achieving greater market success. The increasing focus on patient-centric drug development and the advancements in formulation technologies will likely continue to drive innovation within the 505(b)(2) space. Future trends may include an even greater emphasis on personalized medicine through tailored formulations, the development of more sophisticated drug-device combinations, and the application of cutting-edge drug delivery systems to improve therapeutic outcomes and patient quality of life. As the pharmaceutical landscape continues to evolve, the 505(b)(2) pathway will undoubtedly remain a crucial avenue for bringing innovative and value-added medicines to patients.

REFERENCES

1. Allen, L. V., & Popovich, N. G. (2004). Remington: The science and practice of pharmacy (20th ed.). Lippincott Williams & Wilkins.
2. Behrens, P., & Dressman, J. B. (1991). Solubility of weak acids and bases. European Journal of Pharmaceutical Sciences, 1(6), 363–372. https://doi.org/10.1016/0928-0987(91)90023-K
3. Berndt, E. R. (2002). The U.S. pharmaceutical industry: Why are profits so high? Health Affairs, 21(2), 78–93. https://doi.org/10.1377/hlthaff.21.2.78
4. Bolla, M., & Hutchison, M. (2010). Single enantiomer drugs: Regulatory and marketing perspectives. Chirality, 22(S1), E82–E90. https://doi.org/10.1002/chir.20892
5. Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008). Medication compliance and persistence: Terminology and definitions. Value in Health, 11(1), 44–47. https://doi.org/10.1111/j.1524-4733.2007.00213.x
6. Dixit, R. P., & Shivhare, U. S. (2011). Orally dissolving films: A review. Journal of Controlled Release, 151(3), 332–341. https://doi.org/10.1016/j.jconrel.2011.01.034
7. Dobetti, L. (2001). Fast-melting tablets: Developments and technologies. Pharmaceutical Technology Europe, 13(9), 32–42.
8. European Medicines Agency. (2019). Guideline on quality requirements for drug-device combinations. https://www.ema.europa.eu
9. Ferrari, M. (2005). Cancer nanotechnology: Opportunities and challenges. Nature Reviews Cancer, 5(3), 161–171. https://doi.org/10.1038/nrc1566
10. Food and Drug Administration. (1999). New drug and antibiotic regulations; final rule. Federal Register, 64(120), 32448–32458.
11. Freiberg, S., & Zhu, X. X. (2004). Polymer microspheres for controlled drug release. International Journal of Pharmaceutics, 282(1–2), 1–18. https://doi.org/10.1016/j.ijpharm.2004.07.009
12. Gansler, T., Squillante, E., & Roman, R. (2012). The 505(b)(2) pathway: Facilitating innovation while leveraging existing data. Pharmaceutical Outsourcing, 13(4), 18–21.
13. Garber, A. J., Davidson, J. A., Schlussel, Y., St. Peter, J. V., & Poon, T. H. (2003). Efficacy of once-daily extended-release metformin in patients with type 2 diabetes: A 24-week, double-blind, placebo-controlled study. Diabetes, Obesity and Metabolism, 5(2), 99–104. https://doi.org/10.1046/j.1463-1326.2003.00264.x
14. Gharse, S., Suryawanshi, S., & Shinde, S. (2012). Pulsatile drug delivery systems: A review. International Journal of Pharmaceutical Sciences and Research, 3(11), 4101–4109.
15. Grabowski, H. G., & Ridley, D. B. (2016). Generic entry prior to patent expiration: An empirical analysis of U.S. pharmaceutical patent challenges. Managerial and Decision Economics, 37(1), 3–15. https://doi.org/10.1002/mde.2715
16. Gregoriadis, G. (2016). Liposomes. In Nanomaterials for drug delivery and therapy (pp. 3–30). Pan Stanford Publishing.
17. Hough, D., Gopal, S., Vijapurkar, U., Lim, P., Morozova, M., & Eerdekens, M. (2010). Paliperidone palmitate long-acting injection: A 13-week, randomized, placebo-controlled study. Schizophrenia Research, 116(2–3), 107–115. https://doi.org/10.1016/j.schres.2009.10.027
18. Kane, J. M., Eerdekens, M., Lindenmayer, J. P., Schreiner, A., & Lesem, M. (2003). A multicenter, randomized, double-blind, placebo-controlled trial of orally disintegrating risperidone in acutely psychotic patients. Journal of Clinical Psychiatry, 64(10), 1238–1246. https://doi.org/10.4088/JCP.v64n1008
19. Krishna, R., & Bharatam, P. V. (2009). Prodrugs for improved oral bioavailability: Targeted enzyme activation to achieve site-specific drug delivery. Advanced Drug Delivery Reviews, 61(11), 949–970. https://doi.org/10.1016/j.addr.2009.06.007
20. Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England Journal of Medicine, 353(5), 487–497. https://doi.org/10.1056/NEJMra050100
21. Rautio, J., Kumpulainen, H., Heikonen, T., Kostiainen, R., & Järvinen, T. (2008). Prodrugs: Design and applications. Nature Reviews Drug Discovery, 7(3), 255–270. https://doi.org/10.1038/nrd2468
22. Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. Journal of Controlled Release, 70(1–2), 1–20. https://doi.org/10.1016/S0168-3659(00)00339-4
23. Thomas, S. M. (2011). Pharmaceutical patent law. John Wiley & Sons.
24. Thombre, A. G., & Appel, L. E. (2005). Oral osmotic drug delivery systems. Advanced Drug Delivery Reviews, 57(12), 1791–1822. https://doi.org/10.1016/j.addr.2005.07.002
25. Torchilin, V. P. (2006). Targeted pharmaceutical nanocarriers for cancer therapy. Nature Reviews Drug Discovery, 5(10), 834–838. https://doi.org/10.1038/nrd2090
26. Premier Consulting. (2021, April 14). 2020 505(b)(2) NDA approvals: A year in review, and what a year it was! https://premierconsulting.com/2020-505b2-nda-approvals-a-year-in-review
27. U.S. Food and Drug Administration. (1995). Extended Release OxyContin (NDA 022272). https://www.accessdata.fda.gov/drugsatfda_docs/nda/1995/022272_OxyContin.cfm
28. U.S. Food and Drug Administration. (2009). Glumetza (metformin hydrochloride extended-release) (NDA 021723). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021723s000SumR.pdf
29. U.S. Food and Drug Administration. (2006). Zegerid Delayed-Release (NDA 021849). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/021849s000ltr.pdf
30. U.S. Food and Drug Administration. (2005). Doryx Delayed-Release (NDA 050795). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/050795s000_Doryx_Approv.pdf
31. U.S. Food and Drug Administration. (2017). Covera-HS (NDA 020552). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/020552Orig1s010ltr.pdf
32. U.S. Food and Drug Administration. (2003). Uniphyl (NDA 018092). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/018092s033ltr.pdf
33. U.S. Food and Drug Administration. (2016). Abilify Discmelt (NDA 021729). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/021729Orig1s024.pdf
34. U.S. Food and Drug Administration. (2019). Exservan (NDA 212640). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/212640Orig1s000ltr.pdf
35. U.S. Food and Drug Administration. (2014). Bunavail (NDA 205637). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205637Orig1s000ltr.pdf
36. U.S. Food and Drug Administration. (2003). Methylin Chewable Tablets (NDA 021475). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021475s000_MethylinTOC.cfm
37. U.S. Food and Drug Administration. (2024). Eohilia (NDA 213976). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/213976Orig1s000ltr.pdf
38. U.S. Food and Drug Administration. (2024). Tecentriq Hybreza (BLA761347). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761347Orig1s000ltr.pdf
39. U.S. Food and Drug Administration. (n.d.). MiniMed 770G (PMA P160017/S076). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160017S076.